2021
DOI: 10.1089/jpm.2020.0159
|View full text |Cite
|
Sign up to set email alerts
|

Evaluating the Thresholds for Clinical Importance of the EORTC QLQ-C15-PAL in Patients Receiving Palliative Treatment

Abstract: Background: The EORTC QLQ-C15-PAL is a shortened version of the widely used EORTC QLQ-C30. This questionnaire was developed to measure the symptoms and functional health of patients receiving palliative care. Objective: To enhance clinical interpretability of the EORTC QLQ-C15-PAL, our aim was to evaluate the sensitivity and specificity of thresholds for clinical importance developed previously for the QLQ-C30 when applied to the QLQ-C15-PAL scales. Design: Cross-sectional observational study. Setting/Subjects… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
7
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
2
1

Relationship

1
7

Authors

Journals

citations
Cited by 13 publications
(8 citation statements)
references
References 50 publications
0
7
1
Order By: Relevance
“…The questionnaires consisted of: Brief Pain Inventory (BPI), European Organisation for Research and Treatment of Cancer quality of life questionnaires (EORTC-C15-PAL and EORTC-BM22) and the Euro-QoL five-dimensional instrument of health-related quality of life (EQ5D-3L). [11][12][13][14] The PRESENT-study was approved by the Medical Ethics Committee of the UMCU (NL49273.041.14, METC 13/261) and was registered on clinicaltrials.gov (NCT02356497). For the current study, an additional COVID-19 specific questionnaire was sent out to active PRESENT cohort patients who had given informed consent to receive quality of life questionnaires.…”
Section: Study Design and Participantsmentioning
confidence: 99%
“…The questionnaires consisted of: Brief Pain Inventory (BPI), European Organisation for Research and Treatment of Cancer quality of life questionnaires (EORTC-C15-PAL and EORTC-BM22) and the Euro-QoL five-dimensional instrument of health-related quality of life (EQ5D-3L). [11][12][13][14] The PRESENT-study was approved by the Medical Ethics Committee of the UMCU (NL49273.041.14, METC 13/261) and was registered on clinicaltrials.gov (NCT02356497). For the current study, an additional COVID-19 specific questionnaire was sent out to active PRESENT cohort patients who had given informed consent to receive quality of life questionnaires.…”
Section: Study Design and Participantsmentioning
confidence: 99%
“… 26 The reported statistically significant difference of 7.7 points at 6 months can however not be regarded as clinically important based on previous validation research. 27 , 28 The percentage of patients with serious TRAEs was higher in the TIL study arm (100% versus 57.3%). It was not reported whether there had been toxic deaths in either study arm.…”
Section: Innovative Treatmentsmentioning
confidence: 92%
“…Sensitivity analyses were performed for variables with statistically significant association to the outcomes by dichotomizing at two different cut-off points reflecting if the patient “experienced” the symptom/problem scores of ≥ 33 (a little) and experienced the symptom/problem “severely” with scores of ≥ 66 (quite a bit and very much) [ 32 ] . All adjusted analyses were adjusted for age, sex, cancer site, metastases, comorbidity, physical function, pain, and overall QoL.…”
Section: Methodsmentioning
confidence: 99%